PL2458992T3 - Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu - Google Patents

Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu

Info

Publication number
PL2458992T3
PL2458992T3 PL10804826T PL10804826T PL2458992T3 PL 2458992 T3 PL2458992 T3 PL 2458992T3 PL 10804826 T PL10804826 T PL 10804826T PL 10804826 T PL10804826 T PL 10804826T PL 2458992 T3 PL2458992 T3 PL 2458992T3
Authority
PL
Poland
Prior art keywords
laquinimod
crohn
disease
treatment
Prior art date
Application number
PL10804826T
Other languages
English (en)
Inventor
Nora Tarcic
Asi Haviv
Eran Blaugrund
Joel Kaye
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PL2458992T3 publication Critical patent/PL2458992T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL10804826T 2009-07-30 2010-07-29 Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu PL2458992T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27316709P 2009-07-30 2009-07-30
EP10804826.5A EP2458992B1 (en) 2009-07-30 2010-07-29 Treatment of crohn's disease with laquinimod
PCT/US2010/002129 WO2011014255A1 (en) 2009-07-30 2010-07-29 Treatment of crohn's disease with laquinimod

Publications (1)

Publication Number Publication Date
PL2458992T3 true PL2458992T3 (pl) 2016-07-29

Family

ID=43527240

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10804826T PL2458992T3 (pl) 2009-07-30 2010-07-29 Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu

Country Status (21)

Country Link
US (8) US8598203B2 (pl)
EP (1) EP2458992B1 (pl)
JP (1) JP5882208B2 (pl)
KR (2) KR20120045032A (pl)
CN (2) CN102480960A (pl)
AU (3) AU2010276748A1 (pl)
BR (1) BR112012002124A2 (pl)
CA (1) CA2769623A1 (pl)
DK (1) DK2458992T3 (pl)
EA (1) EA025468B1 (pl)
ES (1) ES2564931T3 (pl)
HR (1) HRP20160189T1 (pl)
HU (1) HUE027680T2 (pl)
IL (1) IL217768A (pl)
ME (1) ME02414B (pl)
MX (1) MX2012001333A (pl)
PL (1) PL2458992T3 (pl)
RS (1) RS54707B1 (pl)
SI (1) SI2458992T1 (pl)
SM (1) SMT201600116B (pl)
WO (1) WO2011014255A1 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1937642T3 (en) * 2005-10-19 2014-12-15 Teva Pharma Crystals of sodium laquinimod and the process for its preparation
EA018031B1 (ru) 2006-06-12 2013-05-30 Тева Фармасьютикал Индастриз, Лтд. Стабильные препараты лаквинимода
PT2682120T (pt) 2007-12-20 2016-11-07 Teva Pharma Preparações de laquinimod estáveis
WO2010028015A2 (en) * 2008-09-03 2010-03-11 Auspex Pharmaceuticals, Inc 2-oxo-1,2-dihydro-quinoline modulators of immune function
JP5882208B2 (ja) * 2009-07-30 2016-03-09 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドによるクローン病の治療
EA201290837A1 (ru) * 2010-03-03 2013-05-30 Тева Фармасьютикал Индастриз Лтд. Лечение волчаночного нефрита с применением лаквинимода
CN102781239B (zh) * 2010-03-03 2015-01-21 泰华制药工业有限公司 使用拉喹莫德治疗狼疮关节炎
SI2542079T1 (sl) * 2010-03-03 2014-08-29 Teva Pharmaceutical Industries Ltd. Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata
KR20130092558A (ko) 2010-07-09 2013-08-20 테바 파마슈티컬 인더스트리즈 리미티드 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도
JP2014530821A (ja) 2011-10-12 2014-11-20 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
WO2013116657A1 (en) * 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
JP2016513665A (ja) 2013-03-14 2016-05-16 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドの経皮製剤
MX2016006256A (es) * 2013-11-15 2016-09-07 Teva Pharma Tratamiento de glaucoma usando laquinimod.
EP3094330A4 (en) * 2014-01-17 2017-09-27 Teva Pharmaceutical Industries Ltd Treatment of crohn's disease using low doses of laquinimod
SG11201608674UA (en) 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US9703929B2 (en) 2014-10-21 2017-07-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
WO2018035330A1 (en) * 2016-08-19 2018-02-22 Janssen Biotech, Inc. Methods of treating crohn's disease with an anti-nkg2d antibody
GB202006390D0 (en) 2020-04-30 2020-06-17 Aqilion Ab Novel treatments

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3024257A (en) * 1961-04-10 1962-03-06 Frosst & Co Charles E Stable preparations of alkali metal salts of estrone sulfate
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
US6696407B1 (en) * 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
US6328762B1 (en) * 1999-04-27 2001-12-11 Sulzer Biologics, Inc. Prosthetic grafts
US6395750B1 (en) * 1999-10-25 2002-05-28 Active Biotech Ab Drugs for the treatment of malignant tumors
EP1365794A2 (en) * 2000-07-21 2003-12-03 Lue, Tom Prevention and treatment of sexual arousal disorders
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6802422B2 (en) * 2000-12-12 2004-10-12 Multi-Comp, Inc. Sealed blister assembly
US6706733B2 (en) * 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US20030119826A1 (en) * 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
PE20050232A1 (es) * 2003-06-25 2005-04-01 Elan Pharm Inc Metodo y composiciones para tratar la artritis reumatoide
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
CA2561164A1 (en) * 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
WO2006029036A2 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
ES2572811T3 (es) * 2004-09-09 2016-06-02 Yeda Research And Development Co., Ltd. Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US20070011731A1 (en) 2005-06-30 2007-01-11 Nokia Corporation Method, system & computer program product for discovering characteristics of middleboxes
US8644246B2 (en) 2005-07-05 2014-02-04 Nokia Corporation Scheduling information at serving cell change
PL1904048T3 (pl) * 2005-07-15 2012-04-30 Merck Serono Sa Inhibitory Glepp-1 w leczeniu zaburzeń autoimmunizacyjnych i/lub zapalnych
NZ597082A (en) * 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
DK1937642T3 (en) * 2005-10-19 2014-12-15 Teva Pharma Crystals of sodium laquinimod and the process for its preparation
CA2623879C (en) * 2005-10-26 2014-03-25 Laboratoires Serono S.A. Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
US20080108641A1 (en) * 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
JP2009531295A (ja) * 2006-02-22 2009-09-03 ユニバーシティ オブ チューリッヒ 自己免疫疾患又は脱髄疾患を処置するための方法
LT2676967T (lt) * 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
US8410115B2 (en) * 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
AU2007224228B2 (en) * 2006-03-03 2013-09-19 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
EA018031B1 (ru) * 2006-06-12 2013-05-30 Тева Фармасьютикал Индастриз, Лтд. Стабильные препараты лаквинимода
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
WO2008021368A2 (en) * 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
CA2673398A1 (en) 2006-12-19 2008-07-03 Merrimack Pharmaceuticals, Inc. Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2008085484A2 (en) * 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
EP2567699A1 (en) * 2007-07-11 2013-03-13 MediciNova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
US20110111070A1 (en) * 2007-10-25 2011-05-12 Yung-Chi Cheng Use of phy906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome
PT2682120T (pt) * 2007-12-20 2016-11-07 Teva Pharma Preparações de laquinimod estáveis
WO2010028015A2 (en) * 2008-09-03 2010-03-11 Auspex Pharmaceuticals, Inc 2-oxo-1,2-dihydro-quinoline modulators of immune function
CA2743717A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
JP5882208B2 (ja) * 2009-07-30 2016-03-09 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドによるクローン病の治療
AU2010282948C1 (en) * 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
CN102781239B (zh) * 2010-03-03 2015-01-21 泰华制药工业有限公司 使用拉喹莫德治疗狼疮关节炎
SI2542079T1 (sl) * 2010-03-03 2014-08-29 Teva Pharmaceutical Industries Ltd. Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata
EA201290837A1 (ru) * 2010-03-03 2013-05-30 Тева Фармасьютикал Индастриз Лтд. Лечение волчаночного нефрита с применением лаквинимода
KR20130092558A (ko) * 2010-07-09 2013-08-20 테바 파마슈티컬 인더스트리즈 리미티드 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도
KR20130041193A (ko) * 2010-07-09 2013-04-24 테바 파마슈티컬 인더스트리즈 리미티드 5-클로로-4-하이드록시-1-메틸-2-옥소-n-페닐-1,2-다이하이드로퀴놀린-3-카복스아마이드, 염 및 그의 용도
MX2013006464A (es) * 2010-12-07 2013-07-29 Teva Pharma Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple.

Also Published As

Publication number Publication date
SI2458992T1 (sl) 2016-03-31
EP2458992B1 (en) 2015-12-16
US20180000812A1 (en) 2018-01-04
US8598203B2 (en) 2013-12-03
CN102480960A (zh) 2012-05-30
JP2013500332A (ja) 2013-01-07
AU2016202216A1 (en) 2016-05-05
BR112012002124A2 (pt) 2015-09-15
RS54707B1 (sr) 2016-08-31
ME02414B (me) 2016-09-20
US20110027219A1 (en) 2011-02-03
EP2458992A1 (en) 2012-06-06
IL217768A0 (en) 2012-03-29
JP5882208B2 (ja) 2016-03-09
EA025468B1 (ru) 2016-12-30
HUE027680T2 (en) 2016-11-28
AU2017254814A1 (en) 2017-11-16
CA2769623A1 (en) 2011-02-03
EA201270221A1 (ru) 2012-08-30
EP2458992A4 (en) 2013-02-20
IL217768A (en) 2017-11-30
KR20160148050A (ko) 2016-12-23
MX2012001333A (es) 2012-06-01
DK2458992T3 (en) 2016-02-08
US20170136003A1 (en) 2017-05-18
CN105616410A (zh) 2016-06-01
SMT201600116B (it) 2016-07-01
US20140200243A1 (en) 2014-07-17
US20170020857A1 (en) 2017-01-26
WO2011014255A1 (en) 2011-02-03
HRP20160189T1 (hr) 2016-05-20
HK1171168A1 (zh) 2013-03-22
WO2011014255A8 (en) 2012-03-15
KR20120045032A (ko) 2012-05-08
AU2010276748A1 (en) 2012-03-15
US20140057883A1 (en) 2014-02-27
ES2564931T3 (es) 2016-03-30
US20170266180A1 (en) 2017-09-21
US20160296512A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
IL217768A0 (en) Treatment of crohn's disease with laquinimod
PL3064206T3 (pl) Leczenie choroby Huntingtona z zastosowaniem lakwinimodu
IL252699A0 (en) Use of lequinimod to treat multiple sclerosis
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
ZA201202596B (en) Compounds for the treatment of dyslipidemia and related diseases
GB0921075D0 (en) Novel combination of the therapeutic agents
GB0908193D0 (en) Treatment of disease state
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
IL218143A0 (en) Substituted heterocyclic derivatives for the treatment of pain and epilepsy
IL260078B (en) Therapy used to treat Gaucher disease
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
GB201021397D0 (en) Diagnosis of Crohn's disease
EP2480099A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING METABOLIC DISEASES
IL223219A0 (en) Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
ZA201005770B (en) The treatment of damaged skin
PT2456445E (pt) Agente para o tratamento de condições da pele
GB201017857D0 (en) Methods for diagnosis and methods of treatment
GB201018362D0 (en) Treatment of dupuytren's disease
GB201018325D0 (en) Treatment for dupuytren's disease
GB0908666D0 (en) Treatment of proteostatic disease
GB201113718D0 (en) Treatment of Dupuytren's Disease
GB0819543D0 (en) Treatment of proteostatic disease
GB0817859D0 (en) Treatment of proteostatic disease
GB0901727D0 (en) The treatment of ophthalmic diseases